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Abstract
Background & Aims: Liver stiffness measured with 2-dimensional shear wave elas-
tography by Supersonic Imagine (2DSWE-SSI) is well-established for fibrosis diagnos-
tics, but non-conclusive for portal hypertension.
Methods: We performed an individual patient data meta-analysis of 2DSWE-SSI to 
identify clinically significant portal hypertension (CSPH), severe portal hyperten-
sion and large varices in cirrhosis patients, using hepatic venous pressure gradient 
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1  | INTRODUC TION
Chronic liver disease costs 39 million disability-adjusted life years 
annually, with decompensated cirrhosis driving excess morbidity 
and mortality.1 The consequence of a change from compensated to 
decompensated cirrhosis is most obvious in 5-year mortality rates, 
which increase from 1.5% in compensated cirrhosis to 88% in cirrho-
sis with multiple decompensating events.2 In compensated cirrho-
sis, the risk of developing varices, and the risk of decompensation, 
increases dramatically when the hepatic venous pressure gradient 
(HVPG) is ≥10 or ≥12 mmHg, marking the thresholds for clinically 
significant portal hypertension (CSPH) and severe portal hyperten-
sion (SPH).3,4 Liver vein catheterization with measurement of HVPG 
is the diagnostic gold standard for the indirect portal pressure as-
sessment in patients with cirrhosis, but the procedure is restricted to 
highly specialized centres.5 Therefore, non-invasive tools with high 
accuracy to rule in or rule out CSPH, SPH and varices needing treat-
ment in patients with cirrhosis are needed.
Transient elastography (TE) with FibroScan® (Echosens, France) 
alone or in combination with platelet count and/or spleen diameter 
is widely used for portal hypertension.6,7 TE below 20 kPa is a key 
feature of the Baveno VI criteria to rule out varices needing treat-
ment in patients with compensated advanced chronic liver disease.4 
The applicability of TE is, however, limited in patients with ascites, 
narrow intercostal space, obesity or displaced liver, and has an upper 
measurement limit of 75 kPa.8
A 2-dimensional real-time shear wave elastography (2DSWE-
SSI) combines an elastogram with traditional ultrasound imagine. 
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and upper endoscopy as reference. We used meta-analytical integration of diagnos-
tic accuracies with optimized rule-out (sensitivity-90%) and rule-in (specificity-90%) 
cut-offs.
Results: Five studies from seven centres shared data on 519 patients. After exclu-
sion, we included 328 patients. Eighty-nine (27%) were compensated and 286 (87%) 
had CSPH. 2DSWE-SSI < 14 kPa ruled out CSPH with a summary AUROC (sROC), 
sensitivity and specificity of 0.88, 91% and 37%, and correctly classified 85% of pa-
tients, with minimal between-study heterogeneity. The false negative rate was 60%, 
of which decompensated patients accounted for 78%. 2DSWE-SSI ≥ 32 kPa ruled in 
CSPH with sROC, sensitivity, specificity and correct classifications of 0.83, 47%, 89% 
and 55%. In a subgroup analysis, the 14 kPa cut-off showed consistent sensitivity 
and higher specificity for patients with compensated cirrhosis, without ascites, viral 
aetiology or BMI < 25 kg/m2. 2DSWE-SSI ruled out severe portal hypertension and 
large varices with fewer correctly classified and lower sROC, and with minimal benefit 
for ruling in.
Conclusion: Liver stiffness using 2-dimensional shear wave elastography below 
14 kPa may be used to rule out clinically significant portal hypertension in cirrhosis 
patients, but this would need validation in populations of compensated liver disease. 
2DSWE-SSI cannot predict varices needing treatment.
K E Y W O R D S
Aixplorer, compensated advanced chronic liver disease, Decompensated liver disease, liver 
vein catheterization, supersonic shear imagine
Key points
• This individual patient data meta-analysis combines data 
from 328 patients from five different studies, which 
have examined the role of 2-dimensional shear wave 
elastography by Supersonic Imagine (2DSWE-SSI) to de-
tect clinically significant portal hypertension (CSPH) in 
patients with cirrhosis.
• We found that 2DSWE-SSI may be used to rule out 
CSPH due to a high summary AUROC (sROC) of 0.88 
and sensitivity of 91%, with minimal between-study 
heterogeneity.
• The existing body of evidence is limited by a substantial 
selection bias, as a high proportion of patients had de-
compensated cirrhosis at study inclusion. This impairs 
the generalizability of results from the meta-analysis.
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This allows the operator to visualize the liver while performing 
the elastography. Furthermore, 2DSWE-SSI has no upper limit 
and measurements can be obtained in patients with ascites. 
This makes the technique suited for patients with advanced dis-
ease, where portal hypertension is the main driver of prognosis.8 
However, the studies investigating 2DSWE-SSI to diagnose por-
tal hypertension and its severity have resulted in heterogeneous 
cut-off values, and the role of potential confounders has not been 
investigated.
We hypothesized that 2DSWE-SSI correlates with HVPG and can 
be used as a diagnostic marker of portal hypertension and oesopha-
geal varices. We therefore performed an individual patient data me-
ta-analysis to aggregate existing evidence. Our primary aim was to 
evaluate 2DSWE-SSI for ruling in and ruling out clinically significant 
portal hypertension in patients with cirrhosis, including subgroup 
and sensitivity analyses (compensated cirrhosis, patients without 
ascites, alcohol and viral aetiology, body mass index (BMI) below 
25 kg/m2, beta-blocker treatment and drinking status). Secondary 
aims were to assess the correlation between 2DSWE-SSI and the 
hepatic venous pressure gradient and evaluate the diagnostic accu-
racy of 2DSWE-SSI for severe portal hypertension and oesophageal 
varices.
2  | METHODS
This meta-analysis was based on a multicentre collaboration with 
data from individual patients in previously published studies. The 
study protocol was sent to all authors prior to data collection. Our 
report follows the preferred reporting items for systematic reviews 
and meta-analyses extension for diagnostic test accuracy studies 
(PRISMA-DTA) checklist.9 All included studies were approved by 
their local ethics board.
2.1 | Studies
We searched MEDLINE and Web of Sciences papers written in 
English that reported diagnostic studies with concurrent HVPG and 
2DSWE-SSI measurements using the Supersonic Aixplorer system 
(Supersonic Imagine), in patients with cirrhosis. Last search update 
was 16 May 2019. We combined electronic searches with manual 
searches by scanning relevant reference lists. We invited corre-
sponding authors to participate in this individual patient data meta-
analysis. The search strategy and results can be seen in Table S1.
2.2 | Participants
We included patients for the meta-analysis if the following inclusion 
criteria were met: (a) 2DSWE-SSI performed within 3 weeks from the 
HVPG measurement; (b) 2DSWE-SSI performed with the patient in a 
fasting state; (c) cirrhosis diagnosed by standard clinical, biochemical, 
ultrasonographic, endoscopic and/or histologic characteristics; (d) age 
18-80 years. We excluded patients in case of: (a) disseminated cancer 
disease; (b) hepatocellular carcinoma; (c) right-side cardiac failure NYHA 
class II-IV; (d) any decompensating event including severe infection in 
the interval between 2DSWE-SSI and HVPG measurement; (e) obstruc-
tive cholestasis evidenced by ultrasound; (f) hepatic inflammation evi-
denced by transaminase elevation of more than three times the upper 
limit of normal; and (g) transjugular intrahepatic portosystemic shunt.
2.3 | Index test and outcomes
The index test was 2DSWE-SSI, reported in kilopascals (kPa). The 
description of the technique can be found elsewhere.10 The primary 
outcome was CSPH defined as HVPG ≥ 10 mmHg, measured by he-
patic vein catheterization according to standard.11 Secondary out-
comes were SPH defined as HVPG ≥ 12 mmHg, and oesophageal 
varices needing treatment assessed by endoscopy at the time of 
2DSWE-SSI measurement.4
2.4 | Data extraction and quality assessment
Authors who agreed to participate shared baseline characteristics, 
HVPG- and 2DSWE-SSI measurements for individual study partici-
pants. Shared data were compared to published results from the in-
dividual studies by MBH and MT.
Four authors (MBH, MT, MI and AK) assessed study quality 
using the Quality Assessment of Diagnostic Accuracy Studies-2 
(QUADAS-2) tool, which consists of four components: patient selec-
tion, index tests, reference standard and flow and timing (Figure 1).12 
For each component, we labelled the risk of bias and applicability as 
low, high or unclear. We contacted authors for clarification, if papers 
had unclear risk components.
2.5 | Statistics
We report summary statistics on pooled data as mean ± SD and 
median ± IQR, depending on distribution. For between-group dif-
ferences, we report Student's t test in terms of normally distributed 
data, Wilcoxon rank sum test in terms of non-normally distributed 
data and Fisher's exact test in terms of proportions. The correla-
tion between 2DSWE-SSI and HVPG was assessed by Pearson's 
correlation coefficient. We used area under the receiver operating 
characteristics (AUROC) curve statistics on pooled data to find the 
optimal 2DSWE-SSI cut-offs to rule out (90% sensitivity) and rule 
in (90% specificity) CSPH, SPH and oesophageal varices. Cut-offs 
were rounded to the nearest integer. Next, we used the rule-in 
and rule-out cut-offs to create 2x2 tables for the distribution of 
true positives, false positives, false negatives and true negatives 
within each included study. Next, we used a meta-analytical diag-
nostic accuracy model, based on bivariate logistic regressions, to 
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combine a hierarchical summary receiver operating characteristics 
(sROC) model and a bivariate random-effects model of sensitivity 
and specificity, visualized in sROC plots.13 We report I2 as a meas-
ure of heterogeneity between studies. An I2 value above 30% indi-
cates substantial heterogeneity. We performed subgroup analyses 
on pooled data, owing to the low number of studies. Subgroup 
analyses included compensated cirrhosis, patients without ascites, 
alcohol and viral etiologies, and BMI below 25 kg/m2. We also 
used pooled data to compare the diagnostic accuracy of 2DSWE-
SSI with other non-invasive markers (Meld-Na, liver TE, spleen TE 
and liver stiffness-spleen size-to-platelet ratio risk score [LSPS]) 
using the DeLong test. We considered a P-value below 0.05 as 
statistically significant. We used STATA 15.0 for all analyses, with 
the MIDAS module for meta-analyses (Statacorp LP).
3  | RESULTS
3.1 | Studies
We identified 13 references referring to six studies which fulfilled 
the inclusion criteria of the meta-analysis and invited the corre-
sponding authors to share individual patient data (see trial flow in 
Figure 2). Authors from five studies responded,14-25 while authors 
of one study did not reply.26 Characteristics of the five included 
studies can be seen in Table S1, and a list of excluded studies and 
cause for exclusion can be seen in Table S2. We included four single 
centre studies (Korea, France, Spain and Italy) and one multicentre 
study (Denmark, Germany and Belgium).14-25 Most patients were 
enrolled prospectively,16,18,22-25 with only one centre including pa-
tients enrolled both prospectively and retrospectively.17,19-21 For the 
quality assessment (Figure 1), we considered the included studies 
at low risk of bias for all domains, except regarding patient selec-
tion. We labelled all studies as having a high risk of bias for patient 
selection, because no study restricted inclusions to compensated 
cirrhosis patients only (for inclusion criteria in the individual studies, 
see Table S1). All studies have reported experienced 2DSWE-SSI 
operators with no more than three different operators per study 
(Table S1). Since portal hypertension is a key driver of hepatic de-
compensation, the inclusion of decompensated patients causes a 
high pretest risk of CSPH.
3.2 | Patients
We received data on 519 participants of whom we included 328 for 
the individual patient data meta-analysis, while 191 met our exclu-
sion criteria (Figure 2). The majority of patients had experienced at 
least one decompensating event prior to inclusion (n = 237, 73%). 
Most patients were men (71%), mean age was 56 ± 10 years and al-
cohol was the dominant cause of cirrhosis (53%) (Table 1). Two hun-
dred and sixty-eight (87%) patients had CSPH. Compared to patients 
without CSPH, patients with CSPH had higher Meld-Na and Child-
Pugh scores and a higher proportion with ascites and decompensa-
tion at baseline (Table 1).
3.3 | 2-dimensional real-time shear wave 
elastography to diagnose clinically significant portal 
hypertension
Median 2DSWE-SSI liver stiffness was significantly higher for patients 
with CSPH (32.0 kPa, IQR [22.1-42.1]) compared to patients without 
CSPH (14.2 kPa, IQR [12.7-23.4]; P < .001). The optimal cut-off to 
rule out CSPH was 14.0 kPa (found by maximizing sensitivity to 90%). 
At this cut-off, the sROC was 0.88 (0.85-0.91), summary sensitivity 
was 91% (86%-94%) and summary specificity was 37% (18%-61%) 
(Figure 3, Table 2). Of the 45 patients with 2DSWE-SSI below 14 kPa, 
27 (60%) were false negatives, as they did have HVPG ≥ 10 mmHg. We 
found that 21 (78%) of the 27 false negative patients were decompen-
sated at baseline. The optimal cut-off to rule in CSPH was 32.0 kPa 
(found by maximizing specificity), corresponding to sROC, sensitivity 
F I G U R E  1   Quality assessment. Quality 
of the included studies according to the 
QUADAS-2 tool. The studies are assessed 
in terms of risk of bias and in terms of 
concerns regarding applicability. The 
index test is 2-dimensional real-time shear 
wave elastography by Supersonic Imagine, 
and reference standard is hepatic venous 
pressure gradient
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F I G U R E  2   Flowchart of study and 
patient selection. The five included 
studies were: (1) Multicentre (Denmark, 
Germany, Belgium),14-16 (2) Korea,17-21 
(3) Spain,22 (4) Italy,23 (5) France.24,25 
2DSWE-SSI, 2-dimensional real-time shear 
wave elastography; HCC, hepatocellular 
carcinoma; HVPG, hepatic venous 
pressure gradient; ULN, upper limit of 
normal. †Two patients out of 328 had 
unknown compensation status
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and specificity of 0.83 (0.79-0.86), 47% (36%-60%) and 89% (74%-
96%). Of the 150 patients with 2DSWE-SSI ≥ 32 kPa, five (3%) were 
false positives, with HVPG < 10 mmHg. While sensitivities and spe-
cificities varied substantially between the five included studies, we did 
not detect evidence of heterogeneity, as I2 was 0%-5% (Table 2). Use 
of the 14 kPa and 32 kPa cut-offs resulted in the following: 18 (5.5%) 
true negative and 27 (8%) false negative below 14 kPa; 145 (44%) true 
positive and 5 false positive (1.5%) above 32 kPa; and 136 (41%) in the 
grey zone between 14 and 32 kPa. One hundred and seventeen of the 
136 patients (86%) in the grey zone had CSPH.
 
All HVPG < 10 mmHg HVPG ≥ 10 mmHg
P-value328 (100) 42 (13) 286 (87)
Gender (male) 233 (71) 31 (74) 202 (71) .720
Age (years) 56 ± 10 56 ± 13 56 ± 10 .973
Compensated 
cirrhosisa 
89 (27) 30 (71) 59 (21) <.001
Meld-Na scorea  13 [9, 18] 9 [7, 13] 14 [10, 19] <.001
Child-Pugh scorea  7 [6, 9] 5 [5, 6] 7 [6, 9] <.001
Ascites at 
inclusiona 
163 (50) 6 (14) 157 (55) <.001
Beta-blockera  110 (34) 8 (23) 102 (49) .005
Measurements
2DSWE-SSI (kPa) 30.4 [19.3, 
40.3]
14.2 [12.7, 23.4] 32.0 [22.1, 42.1] <.001
HVPG (mmHg) 16 [12, 20] 7 [6, 9] 17 [13, 20] <.001
Aetiology
NAFLD 19 (6) 3 (7) 16 (6) .721
Alcohol 173 (53) 13 (31) 160 (56) .003
Viral 90 (27) 17 (41) 73 (26) .062
Other 46 (14) 9 (21) 37 (13) .153
Metabolic risk factors
Excess drinkinga  179 (55) 3 (10) 86 (36) .006
Diabetes and/or 
obesitya 
121 (37) 17 (49) 104 (50) 1.00
BMI (kg/m2)a  25 [23, 28] 25 [23, 28] 25 [23, 28] .989
Blood tests
ALT (U/L)a  30 [18, 43] 26 [15, 43] 30 [19, 43] .480
Albumin (g/L)a  31 [27, 36] 38 [31, 43] 30 [27, 35] <.001
Bilirubin 
(μmol/L)a 
23 [14, 47] 15 [10, 22] 25 [15, 51] <.001
INRa  1.2 [1.1, 1.4] 1.0 [0.9, 1.3] 1.2 [1.1, 1.4] <.001
Platelet count 
(109/L)a 





140 [137, 142] 138 [135, 141] <.001
Note: Values are presented as counts (%), mean ± SD or medians [interquartile range]. P-values are 
from Fisher's exact test for proportions, Student's t test for means and Wilcoxon rank sum test for 
medians.
Abbreviations: 2DSWE-SSI, 2-dimensional real-time shear wave elastography by Supersonic 
Imagine; ALT, alanine aminotransferase; BMI, body mass index; HVPG, hepatic venous pressure 
gradient; INR, international normalized ratio of prothrombin time of blood coagulation; Meld-Na, 
model for end-stage liver disease with sodium NAFLD, non-alcoholic fatty liver disease.
aMissing data: two missing for decompensation, 111 for Meld-Na, 10 for Child Pugh score, 7 for 
ascites, 86 for beta-blocker, 58 for prior or current excess drinking, 86 for diabetes and/or obesity, 
36 for BMI, 21 for ALT, 17 for albumin, 16 for bilirubin, 12 for INR, 12 for platelet count and 18 
missing for sodium. 
TA B L E  1   Patient characteristics
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F I G U R E  3   Hierarchical summary receiver operating characteristic plots of sensitivity and specificity. Hierarchical summary receiver 
operating characteristic plots (HSROC) of sensitivity and specificity using (A) a 14 kPa cut-off for 2DSWE-SSI to rule out CSPH (derived by 
optimizing to 90% sensitivity in the pooled data). B, A 32 kPa cut-off to rule in clinically significant portal hypertension (derived by optimizing 
to 90% specificity). C, A 18 kPa cut-off to rule out severe portal hypertension. D, A 36 kPa cut-off to rule in severe portal hypertension. 
The summary operating point presents the summary sensitivity and specificity encircled by a 95% prediction contour of the confidence 
interval. Individual studies are presented with a circle and a number: (1) Multicentre (Denmark, Germany, Belgium), (2) Korea, (3) Spain, 
(4) Italy, (5) France. 2DSWE-SSI, 2-dimensional real-time shear wave elastography by Supersonic Imagine; AUC, area under the summary 
receiver operating characteristic curve; CSPH, clinically significant portal hypertension; HSROC, hierarchical summary receiver operating 
characteristics curve; SENS, sensitivity; SPEC, specificity
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We observed a significant correlation between 2DSWE-SSI and 
HVPG (r = 0.458 P < .001) (Figure 4A). The correlation weakened 
for patients with HVPG < 10 mmHg (r = 0.221, P = .160), but im-
proved for patients without ascites at baseline (r = 0.601, P < .001) 
(Figure 4B and 4C).
3.4 | Subgroup analyses of 2-dimensional shear 
wave elastography by Supersonic Imagine to diagnose 
clinically significant portal hypertension
Subgroup analyses showed that rule out CSPH at the cut-off 14 kPa 
had similar sensitivity and higher specificity for patients with com-
pensated cirrhosis, without ascites, viral aetiology or BMI < 25 kg/
m2 (Table 3). We compared patients receiving beta-blockers 
(n = 110) versus those without beta-blockers (n = 132), and found 
that those on beta-blockers had significantly higher 2DSWE-SSI 
(P = .002), higher rate of varices needing treatment (P < .001), but 
not significantly higher MELD-Na (P = .412). By ROC comparison, no 
significant difference was found between the diagnostic accuracy of 
2DSWE-SSI in patients receiving beta-blockers versus those without 
beta-blocker treatment (P = .312 for CSPH; P = .589 for SPH). We 
had insufficient data on antiviral treatment to justify subgroup anal-
yses. We compared abstinent (n = 130) and drinking patients (n = 96) 
and found no difference in liver stiffness (P = .480) or diagnostic ac-
curacy of 2DSWE-SSI (P = .864 for CSPH; P = .592 for SPH).
To test the robustness of our sensitivity analyses taking into 
account that patients were from different studies, we performed 
a post-hoc multilevel logistic regression with study identifier as a 
random effect. This did not change the subgroup analyses (data not 
shown).
In a post-hoc analysis, we similarly did not find evidence of a cor-
relation between 2DSWE-SSI and transaminases. The correlation 
coefficient between 2DSWE-SSI and ALT was 0.029, while the cor-
relation coefficient for 2DSWE-SSI and AST was 0.146. However, 
as we excluded patients with transaminases above three times the 
upper limit of normal, these results cannot be extrapolated to more 
extreme hepatic inflammation.
We did not have complete data on other non-invasive mark-
ers and scores for comparison with 2DSWE-SSI: Child-Pugh score 
(n = 318 available), TE of the liver (n = 47 available), LSPS (n = 38 
available), Meld-Na score (n = 310 available) and TE of the spleen 
(n = 99 available). In the available data, 2DSWE-SSI was not different 
from Child-Pugh score, liver TE and LSPS for the diagnosis of CSPH 
TA B L E  2   Diagnostic accuracy of 2-dimensional real-time shear wave elastography by Supersonic Imagine to rule out and rule in clinically 















Clinically significant portal hypertension
Rule out 
<14 kPa






















71% (67-75) 15% (7-28) 90% (83-95) 1.6 (0.7-3.3) 0.9 (0.8-1.0) 60 12 76 N/A
12 118
Note: We derived the 2DSWE-SSI rule out cut-offs by optimizing 90% sensitivity in the total cohort. Similarly, we derived the 2DSWE-SSI rule in cut-
offs by optimizing to 90% specificity. Data are reported with 95% confidence interval in parenthesis
2DSWE-SSI, 2-dimensional real-time shear wave elastography by Supersonic Imagine; AUROC, area under the receiver operating characteristic 
curve; FN, false negative; FP, false positive; I2, test for inconsistency between studies; kPa, kilopascal; LR−, negative likelihood; LR+ positive 
likelihood; TN, true negative; TP, true positive.
aData on the presence of oesophageal varices were available for 218 patients with an endoscopy at baseline. 
bTo perform the summary analysis, we replaced true positive, true negative, false negative and false positive containing zeros with 1. 
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F I G U R E  4   Correlation plot. 
Correlation scatter plots with fitted 
lines of 2DSWE-SSI and the hepatic 
venous pressure gradient. The Pearson 
correlation coefficient (r) is reported 
in the upper left part of the graph. (A) 
Correlation between 2DSWE-SSI and 
HVPG for all 328 patients in the meta-
analysis. (B) Correlation between 2DSWE-
SSI and HVPG in the 55 patients without 
clinically significant portal hypertension 
(HVPG ≤ 10 mmHg). (C) Scatter plot of 
the correlation between 2DSWE-SSI and 
HVPG in 158 patients without ascites. 
2DSWE-SSI, 2-dimensional real-time shear 
wave elastography by Supersonic Imagine; 
HVPG, hepatic venous pressure gradient
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(all P > .05), whereas 2DSWE-SSI outperformed Meld-Na and spleen 
TE (P < .05) (Table S3). In post-hoc analyses, we also applied the 
Baveno VI criteria to 2DSWE-SSI instead of TE, to check how many 
patients had platelet count >150*109/L and 2DSWE-SSI < 14 kPa. 
This applied to only 7 of 316 (2%) patients with a platelet count at 
baseline, of whom one had varices needing treatment.
3.5 | 2-dimensional real-time shear wave 
elastography for severe portal hypertension and 
varices needing treatment
A total of 251 (77%) patients had SPH with HVPG ≥ 12 mmHg, and 
88 (40%) had varices needing treatment, in a subgroup of 218 pa-
tients with endoscopy at baseline. Patients with SPH had signifi-
cantly higher 2DSWE-SSI than patients without SPH (33.4 kPa, IQR 
[23.7-44.1] vs 17.2 kPa, IQR [12.9-25.9]; P < .001), but we found no 
significant difference in 2DSWE-SSI for patients with oesophageal 
varices compared to patients without oesophageal varices (32.9 kPa, 
IQR [21.9-44.3] vs 29.3, IQR [19.9-39.4]; P = .124).
The optimal 2DSWE-SSI cut-off to rule out SPH was 18.0 kPa, 
and the optimal cut-off to rule in SPH was 36.0 kPa. For 2DSWE-
SSI below 18 kPa, sROC was 0.89 (0.86-0.92), summary sensitivity 
was 90% (85%-93%) and summary specificity was 46% (27%-67%) 
(Table 2) (Figure 3C and 3D). Of 66 patients with 2DSWE-SSI below 
18 kPa, 26 (39%) were false negative. For 2DSWE-SSI ≥ 36 kPa, 
sROC, summary sensitivity and specificity were 0.66 (0.62-0.70), 
39% (29%-50%) and 89% (77%-95%), respectively, with 9/114 (8%) 
false positive. We found evidence of substantial between-study 
heterogeneity, as I2 was 32% for ruling out SPH at the 18 kPa cut-
off (Table 2). One-hundred and forty-eight patients (45%) were in 
the grey zone of 18-36 kPa. We optimized two cut-offs, 14.0 and 
50.0 kPa, to rule out and rule in varices needing treatment, according 
to sensitivity = 90% and specificity = 90% respectively. For 14.0 kPa, 
sROC was 0.57 (0.52-0.61), summary sensitivity was 90% (95% CI 
78-96), summary specificity was 13% (95% CI 6-24) and 10/28 (36%) 
were false negative. For 50.0 kPa, sROC, sensitivity, and specificity 
were 0.71 (0.67-0.75), 15% (95% CI 7-28), and 90% (95% CI 83-95), 
with 50%  and false positives. However, use of these cut-offs left 166 
(76%) of patients in the grey zone between 14 and 50 kPa (Table 2).
4  | DISCUSSION
In this meta-analysis based on data from five studies and 328 in-
dividual patients, we found that 2-dimensional shear wave elas-
tography by Supersonic Imagine had a high sensitivity to rule out 
clinically significant portal hypertension at cut-off 14 kPa, but 
TA B L E  3   Subgroup diagnostic accuracy, sensitivity and specificity of 2-dimensional real-time shear wave elastography by Supersonic 
Imagine to rule out (<14 kPa) and rule in (≥32 kPa) clinically significant portal hypertension in patients with cirrhosis
 AUROC Sensitivity Specificity LR+ LR−
Correctly 
classified, %
Compensated at baseline (n = 89)
Rule out 0.67 (0.57-0.76) 90% (79-96) 43% (26-63) 1.5 (1.1-2.2) 0.2 (0.1-0.6) 74
Rule in 0.57 (0.51-0.65) 22% (12-35) 93% (78-99) 3.3 (0.7-13.7) 0.8 (0.7-0.9) 46
No ascites (n = 158)
Rule out 0.69 (0.61-0.78) 90% (84-95) 49% (31-66) 1.6 (1.1-2.5) 0.2 (0.1-0.4) 81
Rule in 0.65 (0.59-0.71) 36% (27-45) 94% (81-99) 4.8 (1.0-22.3) 0.7 (0.5-1.0) 49
Alcohol aetiology (n = 173)
Rule out 0.66(0.53-0.80) 94% (90-97) 39% (14-68) 1.5 (0.9-2.3) 0.1 (0.0-0.3) 90
Rule in 0.78 (0.70-0.87) 64% (56-72) 92% (64-100) 8.3 (1.2-55.2) 0.3 (0.2-0.5) 66
Viral aetiology (n = 90)
Rule out 0.70 (0.58-0.83) 88% (78-94) 53% (28-77) 1.8 (1.1-3.1) 0.2 (0.1-0.4) 81
Rule in 0.64 (0.56-0.71) 33% (22-45) 94% (71-100) 5.5 (0.8-38.5) 0.7 (0.5-0.8) 44
BMI < 25 (n = 140)
Rule out 0.73 (0.62-0.84) 96% (91-99) 50% (27-73) 1.8 (1.1-3.0) 0.0 (0.0-0.3) 89
Rule in 0.73 (0.63-0.82) 60% (51-69) 85% (62-97) 4.0 (1.2-12.8) 0.4 (0.3-0.7) 64
Beta-blocker treatment (n = 110)
Rule out 0.72 (0.53-0.91) 94% (88-99) 50% (16-84) 1.9 (0.9-3.8) 0.1 (0.0-0.3) 90
Rule in 0.73 (0.6-0.86) 59% (49-69) 88% (47-100) 4.7 (0.7-29) 0.5 (0.3-0.7) 61
Note: All subgroup analyses were performed on pooled data from the full cohort. We derived the 2DSWE-SSI rule out cut-offs by optimizing to 90% 
sensitivity and rule in cut-offs by optimizing to 90% specificity. All data are reported with 95% confidence interval in parenthesis.
Abbreviations: 2DSWE-SSI, 2-dimensional real-time shear wave elastography by Supersonic Imagine; AUROC, area under the receiver operating 
characteristic curve; BMI, body mass index; I2, test for inconsistency between studies; kPa, kilopascal; LR−, negative likelihood; LR+ positive 
likelihood; N, number; NA, not available.
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also a high false negative rate, as 60% of patients with 2DSWE-
SSI below 14 kPa had CSPH. The high false negative rate is likely 
caused by a high proportion of patients with decompensated 
disease. In contrast, only 3% of patients with 2DSWE-SSI above 
the rule in CSPH cut-off 32 kPa were false positive. Furthermore, 
more than one-third of patients had 2DSWE-SSI between 14 and 
31.9 kPa and could therefore not be classified. We found an even 
higher proportion of patients in the grey zone between rule-out 
and rule-in cut-offs for severe portal hypertension (45%) and 
varices needing treatment (74%), which underlines the difficulty 
of designing decision-making tools for cirrhosis patients when the 
majority are decompensated.
We managed to include all but one published study on 2DSWE-
SSI and HVPG. However, the results may be compromised by 
the limited sample size and a high risk of selection bias due to 
the high proportion of patients with decompensated cirrhosis. 
Furthermore, we could not test the influence of antiviral treat-
ment due to insufficient data. We call for more studies that exclu-
sively evaluate patients with compensated advanced chronic liver 
disease. The identification of cirrhosis patients with CSPH before 
decompensation is important according to a recent RCT, as those 
patients could benefit from primary prevention with non-selec-
tive beta-blockers.27 For this reason, it is unfortunate that existing 
studies primarily represent decompensated patients. In fact, the 
low number of compensated patients (27%) in our study may also 
explain why subgroup analyses showed somewhat conflicting re-
sults: we found lower diagnostic accuracy in patients who were 
compensated at baseline, possibly due to a poor correlation be-
tween 2DSWE-SSI and HVPG in patients without CSPH. This find-
ing is in contrast to studies investigating transient elastography 
for portal hypertension, where the strongest correlation between 
TE and HVPG is observed in patients with HVPG < 10 mmHg.7 
Between-study heterogeneity cannot explain our findings, as I2 
was low.
Currently, TE is the only elastography technique recommended 
by the Baveno group to identify CSPH and, in combination with 
platelet count, to rule out varices needing treatment.4 The Baveno 
VI criteria saves approximately 30% of variceal screening endos-
copies in compensated cirrhosis patients.28 In our cohort, we did 
not find similar results for 2DSWE-SSI, as only 2% of patients had 
2DSWE-SSI below 14 kPa and platelet count above 150*109/L. 
However, this discrepancy may not be due to differences be-
tween TE and 2DSWE-SSI, but rather due to the high proportion 
of decompensated patients in our pooled data, in whom variceal 
screening should always be done. Existing evidence suggests that 
2DSWE-SSI and TE exhibit similar diagnostic accuracies for staging 
fibrosis across aetiologies.10,29 Two of the studies included in this 
meta-analysis similarly found no difference in diagnostic accuracy 
of the two techniques, albeit one study suggested that TE may 
have a higher failure rate than 2DSWE-SSI.22,24 Unfortunately, 
we did not have enough data for a robust meta-analytical com-
parison of TE and 2DSWE-SSI for portal hypertension. Therefore, 
our results should not be interpreted as a rejection of 2DSWE-SSI 
in favour of TE. Rather, new techniques are desirable to avoid 
monopolization.
Between-study variation in cut-off values is considered one of 
the main barriers for implementation of new diagnostic techniques. 
The individual patient data meta-analytical approach enabled us to 
derive consistent cut-offs from the pooled data, to be used in future 
studies. Another advantage was the ability to exclude patients who 
did not fulfil our inclusion and exclusion criteria, thereby limiting 
bias from patients with concomitant hepatic malignancy, severe liver 
inflammation or an extended time between 2DSWE-SSI and HVPG 
measurements.
In conclusion, this individual patient data meta-analysis is the 
largest series to date on 2-dimensional shear wave elastography 
by Supersonic Imagine for portal hypertension in patients with ad-
vanced liver disease. Our findings indicate that a cut-off of 14 kPa 
may be tested in future studies including patients with compensated 
advanced chronic liver disease to rule out clinically significant portal 
hypertension.
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